Table 1 Estimates of baseline trend, level and trend changes, and absolute changes one year after the policy interventions for total antipsychotic sales and for generic market share of major active substances in Finland and Portugal
| Â | Variable | Monthly baseline trend pre-policy | Level change post-policy | Monthly trend change post-policy | Absolute estimated change one year post-policy |
|---|---|---|---|---|---|
(unit) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | |
Finland | Total sales growth per 100,000 population (SU) | 704 (519, 889) | - | -273 (-572, 26) | -3550 (-7354, 254) |
Quetiapine generic market share (%) | 2.07 (1.97, 2.17) | 33.61 (31.61, 35.61) | -2.06 (-2.18, -1.95) | 6.80 (3.92, 9.68) | |
Risperidone generic market share (%) | 2.19 (2.03, 2.34) | 37.65 (34.60, 40.69) | -2.04 (-2.20, -1.88) | 11.13 (6.79, 15.48) | |
Clozapine generic market share (%) | 0.07 (-0.02, 0.17) | 2.22 (0.30, 4.14) | -0.25 (-0.36, -0.13) | -0.97 (-3.75, 1.81) | |
Portugal | Total sales growth per 100,000 population (SU) | - | -4686 (-8913, -458) | - | -4686 (-8758, -613) |
Risperidon generic market share (%) | -0.08 (-0.15, 0.01) | 2.16 (0.76, 3.57) | 0.19 (0.06, 0.31) | 4.59 (2.67, 6.51) | |
Amisulpride generic market share (%) | - | 12.23 (9.61, 14.85) | 0.82 (0.56, 1.09) | 22.95 (21.01, 24.90) |